Pozelimab Biosimilar - Research Grade

Human

C5

5mg/ml

Human IgG4 (S228P)-kappa

CHO Cells

https://www.imgt.org/mAb-DB/

ICH3002

P01031

Blue ice

Complement component C5 governs the terminal complement pathway, generating the potent anaphylatoxin C5a and the membrane attack complex. Offered as an unconjugated, non-therapeutic analog of pozelimab, this research-grade anti-human C5 recombinant monoclonal antibody is intended for research use only. It is manufactured to in vivo quality standards, formulated for low endotoxin, and supplied in scalable milligram (mg) to gram (g) quantities for bulk and high-throughput laboratories. Typical applications include complement inhibition assays, in vitro functional screening, and in vivo models of complement-mediated disease, where it provides a dependable, reproducible reagent.

REGN3918,REGN-3918,complement 5, C5a anaphylatoxin

Detects human C5

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.